14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MBIO vs FBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Fortress Biotech, Inc. (FBIO) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas FBIO carries 50.4/100 (HOLD) at $1.71 (1.2x Forward P/E, -42.8% operating margin).
Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile FBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs FBIO. Trailing 12-month operating profitability (MBIO 0.0% vs FBIO -42.8%) and valuation multiples (MBIO N/M vs FBIO 1.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
FBIO Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $62.7M market capitalization and -42.8% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MBIO vs FBIO Key Questions & Quantitative Answers
As of Nov 16, 2026, Fortress Biotech, Inc. (FBIO) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas FBIO carries 50.4/100 (HOLD) at $1.71 (1.2x Forward P/E, -42.8% operating margin). Technical & Structure Timing Caution: MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4); meanwhile FBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FBIO leads the Growth & Scale pillar: MBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FBIO at +8.7% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (66.1% gross margin, -42.8% operating margin). On trailing 12-month operating scale, MBIO generates N/A in USD-normalized revenue versus $70M for FBIO. In operating R&D and SG&A reinvestment, MBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FBIO.
FBIO screens cheaper on headline valuation multiples. MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas FBIO trades at 1.2x Forward P/E, 0.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBIO (-43.1% ROE) versus FBIO (102.5% ROE) capital efficiency.
In options market volatility and institutional positioning, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 86% Vol realized risk). By comparison, FBIO carries 48.3% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.24β · 64% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.